Medpace doubles early-phase capacity with a new clinical pharmacology unit

Related tags Clinical trial

Medpace CRO clinical pharmacology CPU Phase I
Ohio, US-based CRO Medpace says it has finished work on a new pharmacology unit in Cincinnati and plans to close its old facility in Norwood.

The new 96-bed facility – known as Clinical Pharmacology Unit (CPU) - is designed for Phase I studies and houses a pharmacy, processing labs and patient recruitment staff for both the recruitment and screening of study subjects.

By the end of the year the contract research organisation (CRO) plans to complete work on reference and bioanalytical labs it is also building at the facility.

Medpace president August Troendle said: “The vision for a state of the art campus began in 2008 with the construction of the existing CRO and global headquarters building” adding that “the CPU and the labs complete the fully integrated campus.​”‖

Early-phase investments

The new facility - which doubles privately-owned​ Medpace’s capacity for Phase I trials – is the second purpose built early-phase unit to open in the US this month behind the one set up by CRI Lifetree in Marlton, New Jersey last week.

Similarly UK-based Synexus opened a new in-patient facility in South Africa - its fourth in the country - earlier this week that will conduct Phase II studies as well as later-stage research.

Whether this timing indicates the beginning of a trend – a possible pick-up in demand for early-phase studies? - or is simply a coincidence remains to be seen, but the fact both firms stressed their new units’ capacity for complex trials is interesting.

In September last year Kevin Olsen, president of market intelligence firm ISR Reports, told that in contrast with the claims of Big CRO that have cut Phase I capacity, demand for Phase I studies is stable but sponsors are choosing to work with specialists.

[Large CROs] think the Phase I business has simply gone downhill but we’ve found demand is at least stable​”, Olsen said, suggesting that what big CROs see as a slump is actually a shift in outsourcing spend towards niche providers.

Olson based his claim on a survey of more than 100 Phase I decision makers at pharmaceutical and biotech companies. More than four-fifths of respondents said early stage trials are increasingly complex, with patients now included more often, and this is affecting outsourcing choices.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more